aap Implantate AG / Attractive divestment of Contract Manufacturing subsidiary and Trauma/LOQTEQ® growth of 47% give aap a good start in 2014 . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.
In the first three months of the financial year 2014, aap sales totalled EUR 7.1 million (previous year: EUR 10.4 million). First quarter 2014 sales included only two months of EMCM sales; the divestment was effective as of February 28th. On a like for-like-basis, first quarter 2014 sales (without project sales of EUR 1.5 million in Q1 2013) from continued operations grew 33% from EUR 4.6 million to EUR 6.1 million.
| In EUR million | Q1/2014 | Q1/2013 | Change |
| Sales | 7.1 | 10.4 | -31 % |
| EBITDA | 0.1 | 3.1 | -96 % |
| EBIT | -0.4 | 2.3 | k. A. |
| In EUR million | Q1/2014 | Q1/2013 | Change |
| Sales | 6,1 | 4.6 | 33 % |
| EBITDA | 0.1 | -1.1 -1.1 | >100 % |
| EBIT | -0.4 | -1.6 | 75 %. |
In the first quarter of 2014 the Company continued to deliver on its strategic objectives, as illustrated by the following highlights:
- Strong sales growth of the Trauma/LOQTEQ® product portfolio: +47% (from EUR 1.5 million to EUR 2.2 million); LOQTEQ® growth stand alone of +175%
- Divestment of the non core contract manufacturing subsidiary EMCM for EUR 18 million
- Receiving a US patent on silver coating
The ongoing positive development of the Trauma/ LOQTEQ® portfolio was supported by:
- Sale driver were: Russia, Turkey, Italy, Spain, Czech Republic and Bulgaria
- Filing of registration documents for new LOQTEQ® products in countries such as Russia, Iran, Iraq
- Zero reports of any cold welding events in the first quarter
The Company's R&D activities remain on track, including the further extension of the LOQTEQ® portfolio with one new system in the first quarter of 2014. In February, the Company announced that it was granted a US patent covering its silver coating technology. This promising technology has the potential to prevent infections, one of the fundamental challenges in treating trauma patients. aaps development activities with Chinese partner eontech Co. Ltd. for resorbable magnesium technology is in the advanced stage of selection of the active material and preferred coating.
2014 and 2015 Outlook
As reported earlier, the Company has evaluated strategic options for its Biomaterial/bone cement subsidiary aap Biomaterials GmbH in Dieburg. After a thorough review, the Company believes that the value of both aap Implantate AG and aap Biomaterials GmbH may benefit from a spin off of aap Biomaterials GmbH; with the timing of such a transaction being an important consideration. The management board has appointed an experienced merger & acquisition (M&A) company to assist in the execution of this project.
The Company expects sales for the second quarter to be between EUR 7.6 million and EUR 8.2 million (Second quarter 2013 (excl. EMCM): EUR 6.6 million). The EBITDA forecast for the second quarter amounts between EUR 1.0 million and EUR 1.5 million (Second quarter 2013 (excl. EMCM): EUR 0.2 million).
The management board is reaffirming the sales and EBITDA outlook for the full year of 2014: Sales of EUR 35 million and an EBITDA of between EUR 5 million and EUR 6 million.
_______________________________________
aap Implantate AG (ISIN DE0005066609) - Prime Standard/Regulated Market - All German stock markets -
About aap Implantate AG
aap is a global medical device company headquartered in Berlin, Germany that develops, manufactures and markets innovative biomaterials and implants that are used in orthopedic procedures. The Company's products, which include a full line of plating systems, cannulated screws and bone cement products, are primarily used in the orthopedic specialty areas of trauma and spine repair. The Company's products are sold through its direct sales force, distribution partners and license agreements with OEM partners. aap's stock is listed in the Prime Standard segment of the Frankfurt Stock Exchange. For more information, please visit www.aap.de, or download the Company's investor relations app from the Apple's App Store or Google Play.
Forward-looking statement
This release may contain forward-looking statements based on current experience, estimates and projections of the management board and currently available information. They are not guarantees of future performance. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. Many factors could cause the actual results, performance or achievements of aap to be materially different from those that may be expressed or implied by such statements. These factors include those discussed in aap's public reports. Forward-looking statements therefore speak only as of the date they are made. aap does not assume any obligation to update the forward-looking statements contained in this release or to conform them to future events or developments.
For inquiries please contact: aap Implantate AG, Marc Heydrich, Investor Relations, Lorenzweg 5, 12099 Berlin, Germany
Tel.: +49 30 7501 9-134, fax: +49 30 7501 9-290, e-mail: m.heydrich@aap.de
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: aap Implantate AG via Globenewswire
--- End of Message ---
aap Implantate AG
Lorenzweg 5 Berlin Germany
WKN: 506660;ISIN: DE0005066609;
Listed: Freiverkehr in Börse Stuttgart,
Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg,
Freiverkehr in Börse Berlin,
Freiverkehr in Börse Düsseldorf,
Freiverkehr in Bayerische Börse München,
Freiverkehr in Niedersächsische Börse zu Hannover,
Prime Standard in Frankfurter Wertpapierbörse,
Regulierter Markt in Frankfurter Wertpapierbörse;
